Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Pancreatic ductal adenocarcinoma (PDAC) is the most common malignancy of the pancreas and has one of the highest mortality rates of any cancer type with a 5-year survival rate of <5%. Recent studies of PDAC have provided several transcriptomic classifications based on separate analyses of individual patient cohorts. There is a need to provide a unified transcriptomic PDAC classification driven by therapeutically relevant biologic rationale to inform future treatment strategies. Here, we used an integrative meta-analysis of 353 patients from four different studies to derive a PDAC classification based on immunologic parameters. This consensus clustering approach indicated transcriptomic signatures based on immune infiltrate classified as adaptive, innate and immune-exclusion subtypes. This reveals the existence of microenvironmental interpatient heterogeneity within PDAC and could serve to drive novel therapeutic strategies in PDAC including immune modulation approaches to treating this disease.

Original publication

DOI

10.1002/ijc.32186

Type

Journal article

Journal

Int j cancer

Publication Date

15/08/2019

Volume

145

Pages

1125 - 1137

Keywords

T cells, adaptive immunity, innate immunity, pancreatic cancer, subtypes, tumour microenvironment, Adenocarcinoma, Carcinoma, Pancreatic Ductal, Cluster Analysis, Gene Expression Regulation, Neoplastic, Humans, Immunophenotyping, Pancreatic Neoplasms, Prognosis, Transcription, Genetic, Transcriptome